Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

ABSTRACT:

SUBMITTER: Antonarakis ES 

PROVIDER: S-EPMC4812821 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature